Interview with Sandoz CEO Richard Saynor on Generic Pharmaceuticals Industry
By
jbm
A weekday bagel. Dependable, satisfying, no fuss.
Summary
This article discusses an interview with Richard Saynor, head of Sandoz, focusing on the generic pharmaceuticals industry and its differences from patented drug development. It covers the competitive nature of generic drug manufacturing, pricing dynamics, and intellectual property/regulatory challenges. The piece also references Novo Nordisk's situation in Canada, highlighting industry-specific issues in the pharmaceutical sector.
Key quotes
· 3 pulledGeneric competition can be extremely fierce (and can come down to price, which is much more rare among patented drugs)
There are also a lot of interesting IP and regulatory issues about when you can start making and selling a generic version
That's a part of the industry that I don't cover as much, partly because I've never worked in it and partly because it can be a very different world than the new-drug-discovery-oriented pharma one that I know
You might also wanna read
Replimune to resubmit melanoma drug for FDA approval after agency leadership changes
Replimune plans to resubmit its melanoma drug for FDA approval following a leadership shakeup at the agency. The drug was twice rejected und
cnb.cx·2d ago
GLP-1 weight loss drugs reduce food spending, creating a $6.5 billion challenge for major grocery retailers
The article discusses how GLP-1 weight loss drugs like tirzepatide are significantly impacting consumer spending on food, creating a $6.5 bi
bit.ly·4d ago
Ebola Outbreak Spreads as Eli Lilly Invests $4 Billion in Vaccine Deals
This article covers multiple health and investment topics in a newsletter format. Key points include: the Ebola outbreak in the Democratic R
forbes.com·4d ago
Novo Nordisk loses global market lead to Eli Lilly outside the US
Novo Nordisk, the Danish pharmaceutical giant, is losing its global market leadership to rival Eli Lilly, not just in the crucial US market
finans.dk·4d ago
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·4mo ago
Tylenol-maker's stock declines amid RFK Jr's reported plans to suggest autism link
Shares of Tylenol-maker Kenvue dropped after reports that RFK Jr will suggest a link between acetaminophen use during pregnancy and autism.
bbc.com·8mo ago